Cancer Research Cell Death Mechanisms and Cancer Therapy Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pogribny, I. P.
Right arrow Articles by James, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pogribny, I. P.
Right arrow Articles by James, S. J.
[Cancer Research 60, 588-594, February 1, 2000]
© 2000 American Association for Cancer Research

Carcinogenesis

Single-Site Methylation within the p53 Promoter Region Reduces Gene Expression in a Reporter Gene Construct: Possible in Vivo Relevance during Tumorigenesis1

Igor P. Pogribny, Marta Pogribna, Judith K. Christman and S. Jill James2

Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, Arkansas 72079 [M. P., S. J. J.]; Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205 [I. P. P., S. J. J.]; and Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska 68198 [J. K. C.]

It is not known whether transcriptional suppression by de novo methylation occurs within the promoter region of the p53 gene during multistage tumorigenesis. To address this question, in vivo alterations in the CpG methylation within the rat p53 promoter region were evaluated in control, preneoplastic, and tumor tissue during tumor progression using the folate/methyl-deficient model of hepatocarcinogenesis. Alterations in CpG methylation were found to be site-specific and to vary depending on the stage of carcinogenesis. To further explore the effect of site-specific methylation on p53 promoter activity, reporter gene constructs were prepared containing specifically methylated sites within the p53 promoter region, and the transcriptional activity in cultured mammalian cells was determined in a transient transfection assay. Relative to the unmethylated construct as a positive control, single-site methylation at nucleotide (nt) -450, which occurs 216 nt upstream from the 85-nt minimal promoter region, suppressed promoter activity by 85%. In contrast, single-site methylation at nt -179, which occurs within the minimal essential promoter region, suppressed activity by only 20%. The p53 promoter constructs containing the singly methylated CpG site at nt -450 were then reevaluated for processive changes in methylation status 48 h after transfection, during maximum suppression of promoter activity. Restriction analysis with methylation-sensitive enzymes revealed that de novo methylation had occurred after transfection at previously unmethylated sites. These findings suggest that nt -450 may constitute a critical site for initiation of de novo methylation and processive spreading of methylation associated with transcriptional inactivation of the p53 gene. Furthermore, the results suggest a possible alternative mechanism for the silencing of the p53 gene in tumors that do not have p53 mutations.




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
F. Crea, E. Giovannetti, F. Cortesi, V. Mey, S. Nannizzi, M. I. Gallegos Ruiz, S. Ricciardi, M. Del Tacca, G. J. Peters, and R. Danesi
Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines
Mol. Cancer Ther., July 1, 2009; 8(7): 1964 - 1973.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Knock, L. Deng, Q. Wu, D. Leclerc, X.-l. Wang, and R. Rozen
Low Dietary Folate Initiates Intestinal Tumors in Mice, with Altered Expression of G2-M Checkpoint Regulators Polo-Like Kinase 1 and Cell Division Cycle 25c
Cancer Res., November 1, 2006; 66(21): 10349 - 10356.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
I. P. Pogribny, S. A. Ross, V. P. Tryndyak, M. Pogribna, L. A. Poirier, and T. V. Karpinets
Histone H3 lysine 9 and H4 lysine 20 trimethylation and the expression of Suv4-20h2 and Suv-39h1 histone methyltransferases in hepatocarcinogenesis induced by methyl deficiency in rats
Carcinogenesis, June 1, 2006; 27(6): 1180 - 1186.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. P. Whitman, S. Liu, T. Vukosavljevic, L. J. Rush, L. Yu, C. Liu, M. I. Klisovic, K. Maharry, M. Guimond, M. P. Strout, et al.
The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy
Blood, July 1, 2005; 106(1): 345 - 352.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. R. Hodge, B. Peng, J. C. Cherry, E. M. Hurt, S. D. Fox, J. A. Kelley, D. J. Munroe, and W. L. Farrar
Interleukin 6 Supports the Maintenance of p53 Tumor Suppressor Gene Promoter Methylation
Cancer Res., June 1, 2005; 65(11): 4673 - 4682.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
F. Esfandiari, R. Green, R. F. Cotterman, I. P. Pogribny, S. J. James, and J. W. Miller
Methyl deficiency causes reduction of the methyl-CpG-binding protein, MeCP2, in rat liver
Carcinogenesis, December 1, 2003; 24(12): 1935 - 1940.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
T. D. Pham, N. K. MacLennan, C. T. Chiu, G. S. Laksana, J. L. Hsu, and R. H. Lane
Uteroplacental insufficiency increases apoptosis and alters p53 gene methylation in the full-term IUGR rat kidney
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2003; 285(5): R962 - R970.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
S. J. James, I. P. Pogribny, M. Pogribna, B. J. Miller, S. Jernigan, and S. Melnyk
Mechanisms of DNA Damage, DNA Hypomethylation, and Tumor Progression in the Folate/Methyl-Deficient Rat Model of Hepatocarcinogenesis
J. Nutr., November 1, 2003; 133(11): 3740S - 3747.
[Abstract] [Full Text] [PDF]

Home page
 J BiochemHome page
Y. Satoh, T. Nakagawachi, H. Nakadate, Y. Kaneko, Z. Masaki, T. Mukai, and H. Soejima
Significant Reduction of WT1 Gene Expression, Possibly Due to Epigenetic Alteration in Wilms' Tumor
J. Biochem., March 1, 2003; 133(3): 303 - 308.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
K.-J. Sohn, J. M. Stempak, S. Reid, S. Shirwadkar, J. B. Mason, and Y.-I. Kim
The effect of dietary folate on genomic and p53-specific DNA methylation in rat colon
Carcinogenesis, January 1, 2003; 24(1): 81 - 90.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
A. R. Karpf, B. C. Moore, T. O. Ririe, and D. A. Jones
Activation of the p53 DNA Damage Response Pathway after Inhibition of DNA Methyltransferase by 5-Aza-2'-deoxycytidine
Mol. Pharmacol., April 1, 2001; 59(4): 751 - 757.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.